CORBEVAX Vaccine (E)
The rising infection rate of the Omicron variant is a major cause of concern right now. In light of this, India’s first indigenously developed RBD protein sub-unit vaccine for COVID-19, CORBEVAX has been approved for emergency use by the Drug Controller General of India. The vaccine has been developed by Hyderabad based Biological E limited. The Department of Biotechnology (DBT) and its PSU the Biotechnology Industry Research Assistance Council (BIRAC), have supported CORBEVAX from the pre-clinical stage through Phase III clinical studies.
